Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Posted 1/26/2021 (updated 4/4/2024)
This webinar was a continuation of the previously scheduled Grant Writing Strategies Webinar- Part 1. Pam Baston provided more practical examples of grant writing strategies and techniques from many successful proposals.
Posted 1/12/2021 (updated 4/4/2024)
During this webinar, Pam Baston, Technical Expert Lead with JBS International, Inc., provided practical examples of grant writing strategies and techniques from many successful proposals. This session included tips for: Reviewing the funding opportunity application, Creating the template and action list, Assembling a team & Creating responsive and competitive proposal sections
Posted 6/17/2021 (updated 4/2/2024)
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking.
Objective:To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence
Posted 10/7/2020 (updated 3/29/2024)
This toolkit contains clinical materials targeting treatment of substance use disorder in the acute care setting.
Posted 12/31/2019 (updated 3/28/2024)
To provide a procedure that both Nursing and Correctional Staff can adhere to for the orderly and secure issuance of suboxone.
Posted 6/16/2020 (updated 3/28/2024)
The most effective therapy for people with opioid use disorder involves the use of Food and Drug Administration-approved medications—methadone, buprenorphine, and naltrexone. Despite evidence that this approach, known as medications for opioid use disorder, reduces relapse and saves lives, the vast majority of jails and prisons do not offer this treatment.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).